CTLA4 and sarcoidosis: In cancer treatment, immune checkpoint inhibitors, especially those targeting PD‐1 (Programmed Death‐1) and CTLA‐4 (Cytotoxic T‐Lymphocyte‐Associated Protein 4), have emerged as promising strategies for improving outcomes across a range of malignancies.[178] Their mechanism of action involves unlocking the “brakes” on the immune system, allowing for a more robust immune response against tumors.[162] Given this capability, there's a growing interest in understanding whether these inhibitors could be repurposed for diseases like sarcoidosis.